Sick by Design: How Big Pharma, Regulators, and the Medical Industry Keep Us ILL
A System That Needs You Sick
We are told that the modern health‑care system exists to protect us—from dangerous products, from quacks, from false hope. We are told that strict rules, long approvals, and billion‑dollar trials are the price of safety and “evidence‑based” medicine. Yet millions of patients sense something very different: cures are rare, prices are insane, “approved” treatments often manage rather than resolve disease, and natural or low‑cost options are sidelined or mocked.
This isn’t an accident. It’s the predictable outcome of a system in which pharmaceutical companies, regulators, the medical industry, and many doctors are locked into a set of incentives that reward chronic illness and monetize human suffering. It is not that every individual is consciously corrupt. It is that the machine is built so that everyone gets paid more when you stay sick.
“In a system that profits from chronic illness, health becomes a threat to the business model.”
1. Profit Before Cure: Chronic Disease as a Business Strategy
Pharmaceutical companies are legally obligated to prioritize shareholder value. Under that mandate, a permanent cure—especially a cheap or natural one—is a terrible product. A drug that patients take every day for life is a financial goldmine. A few treatments that completely solve the problem? That’s a one‑time sale.
The industry’s own language gives the game away. Internally, patients are “lives on therapy,” “treatment‑naïve markets,” and “lifetime value.” Entire strategies are built around increasing “treatment persistence” (keeping you on a drug longer) and “market expansion” (finding more people to label as needing it). There is no corresponding metric for “lives cured and off medication forever.” That’s not what Wall Street rewards.
Most scientists and clinicians working in pharma are not villains. They genuinely want to help. But they operate within a financial cage: only molecules that can be patented, priced high, and protected for years are worth the enormous investment required. Simple, non‑patentable remedies, old off‑patent drugs, lifestyle changes, and traditional therapies simply do not fit that model. They may help you, but they do not help the quarterly earnings call.
“A cured patient is a lost customer. The system never forgets that.”
2. The Evidence Trap: Billion‑Dollar Barriers for Natural Remedies
On paper, the rules sound reasonable: if you claim your product treats, cures, or prevents disease, you must prove it. In practice, the bar for proof is set at a level that only giants can reach. Running large, multi‑center randomized trials with long follow‑up and intensive monitoring can cost hundreds of millions or more. That is trivial only for companies expecting billions in sales under patent protection.
Natural substances and supplements don’t have that luxury. You cannot patent turmeric itself, or magnesium, or a centuries‑old herbal formula in its traditional form. Without exclusive rights, no company can guarantee a return on a billion‑dollar trial. So those trials never happen—or if they do, they are small, underfunded, and scattered.
Regulators then turn around and say: “sorry, the evidence is inadequate.” Small foreign trials, traditional use, and observational data are dismissed, while enormous pharma‑funded trials become the “gold standard.” The result is that many natural or low‑cost interventions with promising evidence are legally muzzled. They are allowed to say “supports” or “helps maintain,” but never “treats” or “reverses,” even when they outperform standard care in real‑world practice.
Meanwhile, a drug that squeaks past placebo in a massive trial—often with modest benefit and serious side‑effects—can be marketed with emotional TV ads, disease‑awareness campaigns, and sales reps in every clinic.
“The system demands billion‑dollar proof, then refuses to fund it for anything that can’t be patented.”
3. Doctors and the Medical Industry: In on It, Even When They Don’t Mean to Be
It’s comforting to imagine that doctors stand apart from this machinery, acting purely as patient advocates, untouched by corporate incentives. Reality is messier. Most doctors are not intentionally corrupt, but they work inside a system that nudges them—financially, culturally, and legally—toward drug‑ and procedure‑heavy medicine and away from cheaper or non‑pharmaceutical options.
Here’s how the trap works:
- Training bias: Medical education is dominated by pharmacology, acute care, and guideline‑driven treatment protocols. Nutrition, lifestyle, and integrative approaches are often sidelined or treated superficially. Many doctors simply are not taught how to use non‑drug tools effectively, so they default to what they know: prescriptions and referrals.
- Time pressure: In a 10–15 minute appointment, it’s far easier to prescribe a pill than to deeply explore diet, stress, sleep, environment, and meaningful lifestyle change. The system pays more for procedures and prescriptions than for long conversations.
- Guidelines and fear: Clinical guidelines—often influenced by industry‑funded studies—become de facto law. Deviating too far from them can expose doctors to malpractice risk. So even when a physician suspects that a patient might do better with non‑drug strategies, they feel safer “following the algorithm.”
- Financial incentives: Hospitals and large practices are often rewarded for revenue‑generating activities: imaging, procedures, branded drug usage, specialist referrals. Doctors may have productivity targets measured in relative value units (RVUs) that push them toward doing more, not necessarily better.
Even well‑meaning clinicians get swept along. They are underpaid for taking time, overworked, and bombarded by pharma marketing disguised as “education.” Lunch talks, sponsored conferences, glossy guidelines, peer influence, and subtle perks all pull in the same direction: diagnose quickly, medicate, move on.
So when patients complain that “doctors are in on it,” they’re not wrong in the systemic sense. Many individual doctors are trying their best, but they work in a machine that treats them as prescribers and throughput managers, not as independent healers. The result is the same: more drugs, more procedures, and less attention to non‑profitable paths to health.
“If the system pays doctors to prescribe and operate—but not to listen and prevent—guess what they end up doing.”
4. Regulators as Gatekeepers for Profit, Not Just Safety
Regulatory agencies are presented as neutral referees. They test the evidence, approve or reject products, and police marketing claims. But because of how the rules are written and enforced, they function as gatekeepers to a lucrative club that only big players can enter.
The health‑claim rules are a perfect example. If a small company selling a natural product uses strong language—“treats arthritis,” “reverses diabetes,” “cures depression”—they can be penalized, even if their claims are grounded in real studies and long traditional use. They are forced to use watered‑down phrases while dancing around what they actually see in practice.
Meanwhile, a giant drug company that spends a fortune on formal trials gets to put its drug on TV, sponsor disease‑awareness campaigns, and fill journals with glossy reprints. When that company misleads the public or hides side‑effects, it may eventually pay a fine—a tiny slice of its profits—and move on.
The rules are not inherently evil: demanding proof before allowing disease‑treatment claims makes sense in theory. But when the cost of meeting those rules is unaffordable for anyone but multinationals, the effect is indistinguishable from regulatory capture. The law becomes a moat that protects incumbents and keeps cheaper or non‑patentable competition outside the castle walls.
“When only billion‑dollar companies can afford the rules, the rules stop being neutral.”
5. The Revolving Door: Government, Regulators, and Big Pharma
No discussion of this system is complete without the revolving door—the constant movement of people between government, regulatory agencies, and the industries they are supposed to oversee.
Former drug company executives move into top positions at regulatory agencies. Former regulators then take high‑paying jobs at pharmaceutical companies shortly after leaving public service. Politicians who write health policy accept campaign money, consulting fees, and speaking honoraria from the same companies they are meant to regulate.
This revolving door does not require a secret conspiracy. It quietly shapes priorities and decisions:
- Regulators who know their next career move may depend on not alienating industry are less likely to take truly tough stances.
- Industry lobbyists, many of them former insiders, help write laws and guidance that favor patent extensions, protective pricing structures, and delayed generic competition.
- Politicians avoid reforms that would seriously threaten pharmaceutical profits, even if those reforms would dramatically lower drug prices or expand access to non‑drug therapies.
Patients are told that every decision is “science‑based.” They are not told that the people making those decisions often have past or future paychecks tied to the success of the companies involved. This is not a glitch. It is the system working exactly as designed.
“The same people who approve the drugs today can be on the payroll tomorrow.”
6. “Proven for Thousands of Years”—But Still Illegal to Say So
Many natural and traditional remedies have been used safely and effectively for centuries. That does not mean every traditional practice is perfect or safe, but it does mean we have real‑world evidence that should at least count for something.
Yet the current framework treats thousands of years of human experience as essentially irrelevant. Unless a remedy is run through the modern clinical trial grinder—at enormous cost—it cannot legally be described in clear, disease‑focused terms. It can “support,” it can “promote,” it can “maintain,” but it cannot “treat” or “prevent,” even in cases where traditional use and small modern studies align strongly.
The irony is painful: traditional knowledge is good enough to inspire patented drugs, but not good enough to be spoken aloud in plain language when attached to unpatentable products. The knowledge is stripped, sanitized, and resold back to the public at a premium, while the original remedy remains legally gagged.
“Traditional medicine is allowed to inspire billion‑dollar drugs—but not to speak its own name.”
7. A System That Looks Like a Scam Because It Functions Like One
When people say “this is a scam,” they are pointing at something real. The scam is not that every drug is poison or every doctor is evil. The scam is structural:
- Chronic conditions are more profitable than cures.
- Only patentable products receive the level of investment needed to fully “prove” them under current rules.
- Natural and lifestyle interventions are under‑researched, under‑reimbursed, and often legally muzzled.
- Doctors are trained, timed, and paid to prescribe and bill, not to prevent and deeply heal.
- Regulators enforce rules that are economically survivable only for very large companies.
- The revolving door ensures that rules and enforcement rarely threaten the long‑term profitability of the biggest players.
No single individual has to be consciously malicious for this to be true. The structure ensures that, over time, power and money flow in one direction—and that direction is not toward your long‑term health.
“You’re not crazy for thinking the system is rigged. You’re just paying attention.”
8. What Real Reform Would Require
If we wanted a system that actually prioritized health over profit, we would have to change the incentives at every level, not just swap out a few people at the top.
Some starting points:
- NO MORE IMMUNITY FOR BIG PHARMA
End the blanket liability shields that let pharmaceutical giants dodge accountability for harmful drugs and vaccines. True justice demands they face the same risks as everyone else when profits trump safety. - Hold Non-Profits and Scientists Accountable for Deception
Penalize non-profits and scientists that knowingly provide false information or hide truthful data benefiting their donors, ensuring transparency and stripping tax-exempt status or funding for those prioritizing funders over public health - End Big Pharma Advertising, Lobbying, and Revolving Door
Ban all direct-to-consumer pharmaceutical advertising, prohibit lobbying of politicians by Big Pharma, and end the revolving door with Big Pharma and politicians, FDA, CDC, and other agencies that only severs the profit-driven influence over public health policy. Strict cooling‑off periods and bans on certain industry roles would help ensure regulators and politicians are not quietly auditioning for their next corporate job. - Informed Consent, No More Human Experiments, No More Emergency Orders, No More Warp Speed Operations, No More Mandates
Mandate full, transparent disclosure of all risks before any treatment; ban non-consensual human trials, end emergency orders bypassing oversight, and require Big Pharma to prove safety first, end employment medical requirements – stopping patients as unwitting guinea pigs. Hold all medical personnel, politicians, government employees/subcontractors, and media accountable for false or misleading statements about holistic cures and Big Pharma drugs – which are little more than ads, through strict penalties and legal consequences - End trials requirement for non‑patentable therapies: The market won’t fund rigorous studies on cheap or natural remedies, end trial requirements so patients can get real answers without waiting for a profit motive.
- Real education for doctors: Medical training must give nutrition, lifestyle, and integrative approaches the same depth and seriousness as pharmacology and procedures, not treat them as afterthoughts.
- Paying for outcomes, not volume: Doctors and hospitals should be rewarded for helping patients get off medications, reverse disease, and stay healthy – not for doing more visits, more tests, and more procedures.
- Truthful claims for honest products: Allow specific, truthful statements about non‑patentable therapies especially when they are supported by modern studies and/or long use evidence, while still banning outright fraud.
None of this will be easy, and none of it will be given voluntarily by those who benefit from the current order. But recognizing the structure is the first step toward changing it.
“Health shouldn’t have to compete with profit. The rules should make profit serve health.”